ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. (2022)
Attributed to:
G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.celrep.2022.110757
PubMed Identifier: 35477023
Publication URI: http://europepmc.org/abstract/MED/35477023
Type: Journal Article/Review
Volume: 39
Parent Publication: Cell reports
Issue: 5
ISSN: 22111247